Register entry
Glaukos Corporation
- Registered sites
- 1
- Drug products
- 3
- Live patents
- 7
- Countries
- 1
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingLabellingFinished drug manufacturePackaging
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Glaukos Corporation | San Clemente, CAUnited States | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3012341472 |
Exclusivity
Patents
7Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| IDOSE TR | TRAVOPROST | Jun 2030 |
| IDOSE TR | TRAVOPROST | Oct 2030 |
| IDOSE TR | TRAVOPROST | Feb 2031 |
| MITOSOL | MITOMYCIN | Jan 2028 |
| MITOSOL | MITOMYCIN | Feb 2029 |
| MITOSOL | MITOMYCIN | May 2029 |
Catalogue
Marketed products
3Showing 3 of 3.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| EPIOXA CROSS-LINKING | riboflavin 5-phosphate ophthalmic | KIT | NDA |
| Photrexa Cross-linking Kit | riboflavin 5-phosphate ophthalmic | KIT | NDA |
| iDose TR | Travoprost Intracameral | IMPLANT | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.